|
|
 |
Registry of Lobbyists - Martin G McNeil
To find further information on a company or organization check the Registry of Joint Stock Companies
|
|
| Registration Number | Status | | | 370 | Inactive | | | Initial registration date | Last date of any changes | | 8-June-2005 | 8-June-2005 |
|
Lobbyist's Last Name
McNeil |
Lobbyist's First Name
Martin |
Middle Initial
G |
|
Business Address of Lobbyist
1004 Middlegate Road |
City
Mississauga |
Province/State
ON |
Country
CA |
Postal/Zip Code
L4Y 1M4 |
Telephone
800 565 5877 |
Fax
905 277 0925 |
| |
Business or Firm Name for Lobbyist (if applicable)
AstraZeneca Canada Inc |
Registry of Joint Stock Companies Number
3054445 |
Business Address of Lobbyist's Business or Firm
1004 Middlegate Road |
City
Mississauga |
Province/State
ON |
Country
CA |
Postal/Zip Code
L4Y 1M4 |
Telephone
800 565 5877 |
Fax
905 277 0925 |
|
|
No other beneficiaries of lobbying activities
|
|
|
|
Description of Employer's Business:
AstraZeneca is one of the world's leading pharmaceutical companies. We provide innovative, effective medicines designed to fight disease in important areas of medical need: cancer, cardiovascular, gastrointestinal, infection, neuroscience and respiratory. Our broad product portfolio includes many world leaders and a range of high potential therapies for treating cancer (Casodex, Arimidex and Faslodex), gastrointestinal disease ( Nexium), asthma ( Symbicort), hypertension ( Atacand), high cholesterol ( Crestor), migraine ( Zomig) and schizophrenia ( Seroquel).We employ more than 50,000 people in 150 countries. Most of our 1,500 Canadian employees work at our facility in Mississauga, Ontario, headquarters for manufacturing, clinical research, sales and marketing, and distribution, while over 100 scientists work at our basic pain research centre in Montréal. R&D is the foundation of our success in bringing new products to market. Highly-skilled Canadian scientists are part of a global team that works toward the discovery and design of novel and effective pharmaceutical agents and technologies. Worldwide, we spend US$2 billion annually. In Canada, we invest over CDN$2 million each and every week on research initiatives. |
| |
|
|
|
| Description |
|
| Representations regarding access to medicines, health policy in therapeutic areas, economic policy regarding the innovation environment, intellectual property and patent protection legislation and regulations. |
View
|
|
|
|
|
|
No funding from any government or agency
|
|
No private funding related to lobbying activities
|
|
|
|
|
